Patent intelligence · US
US 12383572
Administration of an anti-activin-a compound to a subject
Administration of an anti-activin-a compound to a subject
Patent details — US 12383572
- Jurisdiction
- US
- Status
- granted
- Grant date
- Aug 12, 2025
- Expiration
- Aug 7, 2045
- Applicant
- Atara Biotherapeutics, Inc.
- Claims
- 3
- CPC classes
- A61K, A61K2039/505, A61K2039/545, A61K31/704
Quick answer
US 12383572 (Administration of an anti-activin-a compound to a subject) is held by Atara Biotherapeutics, Inc.. Status: granted. Granted Aug 12, 2025. Expires Aug 7, 2045 (19 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- Atara Biotherapeutics, Inc.
- Grant date
- Expiration
- Claims
- 3
- CPC classes
- A61K, A61K2039/505, A61K2039/545, A61K31/704, A61K31/7068, A61K38/177
More from Atara Biotherapeutics, Inc.
Related pharmaceutical patents in our USPTO index.
-
US 11925663
Methods of managing tumor flare in adoptive immunotherapy
granted -
US 11541070
Administration of an anti-activin-A compound to a subject
granted -
US 9968586
Mast cell stabilizers treatment for systemic disorders
granted -
US 9962363
Mast cell stabilizers treatment for systemic disorders
granted -
US 9707206
Mast cell stabilizers treatment for systemic disorders
granted -
US 9265749
Methods for the treatment of systemic disorders treatable with mast cell stabilizers, including mast cell related disorders
granted -
US 8501678
Variant activin receptor polypeptides and uses thereof
granted
Frequently asked questions
What is US patent 12383572?
US 12383572 (Administration of an anti-activin-a compound to a subject) is held by Atara Biotherapeutics, Inc.. Status: granted. Granted Aug 12, 2025. Expires Aug 7, 2045 (19 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 12383572?
Atara Biotherapeutics, Inc. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 10 pharmaceutical patents for this assignee.
When does US 12383572 expire?
Our index shows an expiration date of Aug 7, 2045 (19 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.